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Background: South Africa has a generalized and explosive HIV/AIDS epidemic with the largest number of people
infected with HIV-1 in the world. Molecular investigations of HIV-1 diversity can help enhance interventions to
contain and combat the HIV/AIDS epidemic. However, many studies of HIV-1 diversity in South Africa tend to be
limited to the major metropolitan centers and their surrounding provinces. Hardly any studies of HIV diversity have
been undertaken in Mpumalanga Province, and this study sought to investigate the HIV-1 diversity in this province,
as well as establish the occurrence and extent of transmitted antiretroviral drug resistance mutations.
Methods: HIV-1 gag p24, pol p10 and p66/p51, pol p31 and env gp41 gene fragments from 43 participants were
amplified and sequenced. Quality control on the sequences was carried out using the LANL QC online tool. HIV-1
subtype was preliminary assigned using the REGA 3.0 and jpHMM online tools. Subtype for the pol gene fragment
was further designated using the SCUEAL online tool. Phylogenetic analysis was inferred using the Maximum
Likelihood methods in MEGA version 6. HIV-1 antiretroviral drug resistance mutations were determined using the
Stanford database.
Results: Phylogenetic analysis using Maximum Likelihood methods indicated that all sequences in the study
clustered with HIV-1 subtype C. The exception was one putative subtype BC unique recombinant form. Antiretroviral
drug resistance mutations K103N and E138A were also detected, indicating possible transmission of anti-retroviral
drug resistance mutations.
Conclusions: The phylogenetic analysis of the HIV sequences revealed that, by 2009, patients in the Bushbuckridge,
Mpumalanga were predominantly infected with HIV-1 subtype C. However, the generalized, explosive nature of the
HIV/AIDS epidemic in South Africa, in the context of extensive mobility by South Africans who inhabit rural areas,
renders the continued molecular monitoring and surveillance of the epidemic imperative.
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Human immunodeficiency virus (HIV), the etiological
agent of acquired immunodeficiency syndrome (AIDS),
was first isolated more than 30 years ago [1]. By 2013,
an estimated 35 million people were living with HIV-1
globally, of which 24.7 million were living in sub Saharan* Correspondence: susanen@sun.ac.za
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unless otherwise stated.Africa [2]. During this time period, the HIV-1 prevalence
in South Africa was 12.2% (6.4 million people), with 469
000 new infections occurring, suggesting that the epi-
demic is not only generalized, but also explosive [3].
The HIV-1 epidemic in South Africa is characterized
by limited subtype diversity with subtype C accounting
for the majority of infections [4,5]. Other non-C sub-
types, particularly subtypes B and D, have also been
identified [6-8] as well as the occasional unique recom-
binant forms (URFs) [9-15]. Molecular epidemiological
investigations in South Africa have largely focused on
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Cape and Durban in Kwa-Zulu Natal. No subtype in-
formation is available for the Eastern Cape, North
West and Northern Cape provinces and limited infor-
mation is available for the Free State, Limpopo and
Mpumalanga Provinces. HIV-1 prevalence in South
Africa is also characterized by extreme heterogeneity
and there is considerable variation in prevalence
amongst the different provinces and districts in each
province [16]. The highest prevalence is in Kwa-Zulu
Natal with the lowest in the Western Cape Province.
South Africa not only has a generalized and explosive
HIV/AIDS epidemic, its impact also varies significantly in
terms of race, age, gender, and between regions of the
country, with poor, young, African women in rural
Kwa-Zulu Natal bearing a disproportionate burden of
HIV infection [16].
The overall HIV prevalence in Mpumalanga in 2012 was
35.6% [16]. The province consists of 3 districts: Ehlanzeni,
Nkangala and Gert Sibande. The Bushbuckridge Local
Municipality in the Ehlanzeni District in Mpumalanga
Province is a predominantly rural, impoverished area, with
only 14% of the adult population employed and over 85%
of households living below the house hold subsistence level.
Half of males and 14% of females between the ages of 25
and 59 are long-term migrant workers and provide a source
of remittances, which comprise the largest proportion of
the income of the population of Bushbuckridge [17].Figure 1 Geographical location of samples collected in this study. The S
local municipality in the Ehlanzeni district of Mupumalanga is enlarged. The “MMolecular investigations of HIV diversity can help en-
hance interventions to contain and combat the HIV-1
epidemic. With this study, we investigated for the first
time, HIV-1 diversity in Bushbuckridge, Mpumalanga, as
well as the possible occurrence and extent of transmitted
antiretroviral drug resistance mutations.Methods
Study population and RNA extraction
In preparation for HIV prevention trials, a cohort was
developed for enrollment. Ethics approval were obtained
from the Human Research Ethics Committees (HRECs)
from the University of the Witwatersrand (M061129)
and Stellenbosch University (N11/02/054), following
internationally recognized guidelines. The entry point
for this cohort was via a free voluntary counseling and
testing service. After HIV testing, individuals were of-
fered the opportunity to be part of the pre-screening
cohort. Both HIV negative and HIV positive individ-
uals were allowed to join the cohort in preparation for
preventative and therapeutic HIV vaccine trials. Fifty-
one samples were obtained with informed consent as
part of this pre-screening protocol from 43 HIV positive
participants in Bushbuckridge, Mpumalanga (Figure 1).
RNA was extracted from stored plasma samples using a
QIAamp MinElute Virus Spin Kit in a QIAcube automated
extractor (QIAGEN, Dusseldorf, Germany), according toouth African map with 9 provinces is indicated and the Bushbuckridge
aputo corridor” or N4 trunk roadway is highlighted in blue.
Table 1 Primers used in the amplification of the partial
HIV-1 gene products
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at −70°C until used.Primers# Primer sequence 5’ to 3’ HXB2 position*
p24-1 (gag) AGYCAAAATTAYCCYATAGT 1174 - 1193
p24-2 (gag) AGRACYTTRAAYGCATGGGT 1237 - 1256
p24-6 (gag) TGTGWAGCTTGYTCRGCTC 1673 - 1654
p24-7 (gag) CCCTGRCATGCTGTCATCA 1844 - 1826
PR-5′ prot-1 (pol) TAATTTTTTAGGGAAGATC
TGGCCTTCC
2082 - 2109
PR-5′ prot-2 (pol) TCAGAGCAGACCAGAGCC
AACAGCCCCA
2136 - 2163
RT-NE135 (pol) CCTACTAACTTCTGTATGTC
ATTGACAGTCCAGCT
3334 - 3300
RT-MJ4 (pol) CTGTTAGTGCTTTGGTT
CCTCT
3420 - 3399
Poli 5 (integrase) CACACAAAGGRATTGGA
GGAAATG
4162 - 4185
poli7 (integrase) AACAAGTAGATAAATTAG
TCAGT
4186 - 4208
poli6 (integrase) ATACATATGRTGTTTTACT
AARCT
5130 - 5107
poli8 (integrase) TAGTGGGATGTGTACTTC
TGAAC
5217 - 5195Reverse transcriptase polymerase chain reaction (RT-PCR)
of HIV-1 gene fragments
Four genomic regions were targeted for amplification: the
gag p24 region (HXB2 nucleotides 1248 to 1707); a part of
the pol gene, that includes the Protease (PR) and a partial
segment of the Reverse Transcriptase (RT) region (HXB2
nucleotides 2114 to 3335), the Integrase (IN) region
(HXB2 nucleotides 4202 to 5096) and the partial env gp
41 region (HXB2 nucleotides 7877 to 8282). PCR amplifi-
cation and purification was done using previously de-
scribed primers and methods for the partial gag, pol
integrase (IN) and env [18] genes. The partial pol PR/RT
gene was also amplified using primers and a method pre-
viously described [19,20]. Briefly, cDNA synthesis and first
round PCR amplification was done with the Access-RT
PCR system (Promega, Wisconsin, USA), while second
round nested PCR amplification was done with the GoTaq
DNA polymerase system (Promega, Wisconsin, USA).
The oligonucleotide primers used in the amplification of
the gene fragments are listed in Table 1.JH41 (env) CAGCAGGWAGCACKATGGG 7798 - 7816
Env 27 F (env) CTGGYATAGTGCARCARCA 7861 - 7879
Menv19 R (env) AARCCTCCTACTATCATTATRA 8299 - 8278
JH38 (env) GGTGARTATCCCTKCCTAAC 8346 - 8365
#Primer References [18,20].
*Nucleotide position of the primer according to the HXB2 sequence
(K03455) numbering.Sequencing of HIV-1 gene fragments
The cycle sequencing reactions of the partial gene frag-
ments were done with the Big Dye® Terminator v 3.1
Cycle Sequencing Kit (Applied BioSystems, Foster City,
CA, USA) and run on an ABI Prism 3130xl Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA),
according to the manufacturer’s instructions. Both
strands were sequenced using overlapping primers.
Sequencher v 5.1 (Gene Codes Corporation, Ann Arbor,
MI, USA) was used to assemble the trace data into con-
tiguous fragments, which were then verified, edited and
saved as text files for subsequent analysis. All sequences
were checked for quality assurance using the Los Ala-
mos HIV-1 Sequence Quality Analysis tool (http://www.
hiv.lanl.gov/content/sequence/QC/index.html) before fur-
ther analyses and submission to GenBank.Preliminary HIV-1 subtyping using online tools
The REGA HIV-1 subtyping Tool Version 3.0 (http://
dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/
typingtool) was used to preliminary subtype the sequences
[21]. To detect recombinants, we used the jumping profile
Hidden Markov Model (jpHMM-HIV) tool (http://jphmm.
gobics.de) [22]. Subtype Classification Using Evolutionary
Algorithms (SCUEAL) was used to test for both intra and
inter subtype recombinants in the partial HIV-1 pol and IN
sequences (http://www.datamonkey.org/dataupload_scueal.
php) [23].Phylogenetic inference using Maximum likelihood (ML)
The 2010 HIV-1 Group M reference sequence dataset
(n = 39), from the LANL database (http://www.hiv.lanl.
gov/), was used to subtype our sequences, using phylo-
genetic inference. Multiple sequence alignments, com-
prising the partial gag, pol and env sequences, and the
reference dataset, were constructed using MAFFT
v7.017 [24] as implemented in Geneious version R7 cre-
ated by Biomatters (http://www.geneious.com). These
multiple sequence alignments were subsequently codon
aligned using Codon Alignment v1.1.0 (http://www.hiv.
lanl.gov/content/sequence/CodonAlign/codonalign.html)
and manually checked.
The phylogenetic trees for the different HIV-1 genetic
fragments were inferred using ML methods implemented
in MEGA version 6 [25]. To find the most appropriate
evolutionary model for phylogenetic inference, we used
Model Selection (ML) as implemented in MEGA [25]. For
each model, BIC scores (Bayesian Information Criterion),
AICc value (Akaike Information Criterion, corrected),
Maximum Likelihood value (lnL), and a number of differ-
ent parameters were presented. Models with the lowest
BIC scores were considered to describe the substitution
Table 2 Demographic and clinical information of the
participants
Study number Collection Date Age Gender CD4 count
0005A 23/04/2009 16 Female 466
0022A 24/04/2009 32 Female 731
0038 16/03/2009 31 Female 680
0039 17/03/2009 19 Female 307
0040 23/03/2009 23 Female 506
0042A 19/02/2009 26 Female 511
0064A 16/03/2009 25 Male 105
0066A 17/03/2009 22 Female 583
0073 02/04/2009 24 Female 366
0081A 08/04/2009 23 Female 437
0085 14/04/209 32 Female 154
0092A 16/04/2009 23 Female 137
0097A 17/04/2009 25 Female 243
0098A 20/04/2009 24 Female 261
0101A 20/04/2009 30 Female 790
0103 20/04/2009 22 Female 191
0116A 29/07/2009 26 Female 150
0119A 29/04/2009 28 Female 403
0122A 30/04/2009 33 Female 262
0123A 04/05/2009 34 Female 335
0130A 06/05/2009 29 Female 387
0132A 07/05/2009 25 Female 489
0134A 11/05/2009 26 Female 792
0135A 11/05/2009 23 Female 1263
0136A 11/05/2009 23 Female 1192
0143A 25/05/2009 30 Female 353
0147A 27/05/2009 19 Female 785
0152A 03/06/2009 20 Female 691
0165A 22/06/2009 32 Female 198
0173A 29/06/2009 27 Female 367
0185A 02/07/2009 30 Female 311
0189 20/07/2009 33 Female 560
0190A 06/07/2009 37 Female 229
0192A 06/07/2009 41 Female 522
0193A 06/07/2009 29 Female 313
0198A 07/07/2009 27 Female 217
0199A 07/07/2009 30 Female 219
0203A 08/07/2009 25 Female 401
0204A 08/07/2009 21 Female 349
0206A 08/07/2009 31 Male 314
0207A 08/07/2009 22 Female 733
0211 08/07/2009 31 Female 312
0215A 09/07/2009 22 Female 726
Msimanga et al. Virology Journal  (2015) 12:24 Page 4 of 13pattern the best [25]. For the partial pol PR/RT region, the
Integrase (IN) region and the partial env gp 41 region, the
BIC, AICc and lnL scores indicated that the General Time
Reversible model of evolution with Gamma distribution
and invariant rate among sites (GTR +G + I), was the best
model. For the gag region, the lnL method indicated the
use of the GTR +G + I model and BIC and AICc indicated
the use of the TN93 + G + I model. All nucleotide posi-
tions in the alignments with less than 95% site cover-
age were eliminated, thus fewer than 5% alignment
gaps, missing data, and ambiguous bases were allowed
at any position. The reliability of the inferred trees was
evaluated using bootstrap resampling and branches with a
bootstrap value of 70% or greater were considered reliable
(n = 100) [26].
HIV-1 antiretroviral drug resistance mutations using HIVdb
HIV-1 PR and RT antiretroviral drug resistance muta-
tions were determined using the Stanford University
HIV Drug Resistance Database (HIVdb), http://www.
hivdb.stanford.edu/ [27].
GenBank accession numbers
GenBank accession numbers of the gag sequences were
KM218392 to KM218428; pol sequences, KM218448 to
KM218460; integrase sequences, KM218429 to KM218447
and for the env sequences, KM218357 to KM218391.
Results
Demographic information
The demographic and clinical information of the cohort,
together with the subtyping, are summarized in Table 2.
The study involved 51 plasma samples, collected from
43 participants in Bushbuckridge, between February and
July 2009. Forty samples were collected at the recruit-
ment visit and 11 samples at visit one. Only one sample
per participant was included in the study. All partici-
pants, except for 0064A and 0206A, were female and
none were on HIV-1 antiretroviral treatment. The aver-
age age of the cohort was 26.7 years and ranged from 16
to 41 years. The CD4 lymphocyte count ranged from
105 to 1263 with an average of 450.
PCR amplification, sequence data and quality assurance
PCR amplification was successful for most of the sam-
ples, with 93% (n = 40) of the partial gag p24 gene, 48.8%
(n = 21) of the partial IN p32 gene, and 83.7% (n = 36) of
the partial env gp41 showing positive bands in an agar-
ose gel after electrophoresis. However, the PCR amplifi-
cation of the partial pol PR/RT gene was considerably
less successful at 34.8% (n = 15). PCR amplification of 10
samples were positive in all 4 gene regions and only one
sample, 0116A, could not be amplified in any of the
primers.
Table 3 Intra-subtype C recombinants detected using SQUEAL
Sample Confidence Recombination Intra subtype recombination Breakpoints
0040_pol 0.749277 0.750944 0.750935 112 (111–113); 770 (769–771)
0042A_pol 0.917024 0.945140 0.945136 818 (797–839)
0143A_pol 0.691903 0.957455 0.957454 706 (701–711); 846 (844–848)
0173A_pol 0.736986 0.748732 0.748732 316 (250–382)
0040_IN 0.673024 0.690546 0.690544 551 (499–603)
0098A_IN 0.794292 0.999993 0.999127 172 (171–173); 383 (382–384); 736 (730–742)
Figure 2 Phylogenetic analysis of the partial gag gene, using MEGA 6. A. The evolutionary history was inferred by using the ML method based
on the GTR model. The tree with the highest log likelihood (−5337.9653) is shown. The percentage of trees in which the associated taxa clustered
together is shown next to the branches. A discrete Gamma distribution was used to model evolutionary rate differences among sites (5 categories
(+G, parameter = 1.2415)). The rate variation model allowed for some sites to be evolutionarily invariable ([+I], 52.1407% sites). The tree is drawn to
scale, with branch lengths measured in the number of substitutions per site. The analysis involved 76 nucleotide sequences and included all codon
positions. There were a total of 451 positions in the final dataset. B. The evolutionary history was inferred by using the ML method based on the
Tamura-Nei model (TN93 + G + I). The tree with the highest log likelihood (−5340.4505) is shown. The percentage of trees in which the associated
taxa clustered together is shown next to the branches. A discrete Gamma distribution was used to model evolutionary rate differences among sites
(5 categories (+G, parameter = 1.1914)). The rate variation model allowed for some sites to be evolutionarily invariable ([+I], 51.4597% sites).
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Figure 3 Phylogenetic analysis of the partial pol gene, using MEGA 6. The evolutionary history was inferred by using the ML method based
on the GTR model. The tree with the highest log likelihood (−9574.7386) is shown. The percentage of trees in which the associated taxa clustered
together is shown next to the branches. A discrete Gamma distribution was used to model evolutionary rate differences among sites (5 categories
(+G, parameter = 1.1121)). The rate variation model allowed for some sites to be evolutionarily invariable ([+I], 45.2893% sites). The tree is drawn to scale,
with branch lengths measured in the number of substitutions per site. The analysis involved 49 nucleotide sequences and included all codon positions.
There were a total of 1062 positions in the final dataset.
Msimanga et al. Virology Journal  (2015) 12:24 Page 7 of 13Thirty-seven (86.0%) of the gag p24, 13 (30.2%) of the
pol, RT/PR, 18 (41.8%) of the pol IN and 35 (81.3%) of
the env gp41 amplicons were successfully sequenced.
The LANL QC tool indicated no stop codons, and no
hypermutation was detected in any of the sequences.Preliminary subtype analysis using online tools
REGA and jpHMM online tools were used to assign
subtypes to all the sequences and to detect possible re-
combinant forms. REGA 3.0 assigned all gag, pol PR/RT,
pol IN, and env sequences to subtype C, except for env
0143A, which was assigned subtype B. Similar results
were obtained with jpHMM, with the exception of the
IN region of 0193A which was assigned as a CK recom-
binant form.
The SCUEAL subtyping of the pol PR/RT and IN gene
fragments revealed that all the PR/RT and IN sequences
were HIV-1 subtype C. Six of the sequences (18.75%)
were intra-subtype C recombinant forms (Table 3).ML Phylogenetic inference
Model Selection (ML) using the BIC, implemented in
MEGA, indicated the use of the (GTR +G + I) model for
the pol and env regions and the use of the TN93 + G + I
model for the gag region (Additional files 1, 2, 3 and 4:
Table S1, Table S2, Table S3 and Table S4. Maximum
Likelihood fits of 24 different nucleotide substitution
models for gag, pol PR/RT, pol IN and env gp41, re-
spectively). ML phylogenetic trees were inferred from
the multiple sequence alignments, and branches with a
bootstrap value of 70% or greater were considered reli-
able. None of the sub-genomic regions supported a
monophyletic South African lineage.
In the gag ML tree (Figure 2A and B) all the sequences
clustered within subtype C. Except for slight differences
in the bootstrap values, there were no differences in the
gag tree topologies inferred with either the GTR + G + I
or TN93 + G + I models. Interestingly the 2 outliers to
the main subtype C cluster, 0042A and 0143A, were
possible intra subtype C recombinants in the pol region.
Sequence 0119A had a long branch and 3 sets of se-
quences, 0189A/0203A, 0064A/190A and 0085A/0101A
clustered closely together. This may indicate that these
samples may be a possible PCR contamination or that
they are epidemiologically linked.The ML phylogenetic tree for the pol PR/RT gene
comprised 49 sequences and all the Mpumalanga se-
quences clustered with HIV-1 subtype C (Figure 3). The
ML phylogenetic tree for the IN region contained 55
sequences and all Mpumalanga sequences clustered with
HIV-1 subtype C reference sequences (Figure 4). Sequence
0098A clustered as an outlier to subtype C and SQUEAL
indicated that the sequence is an intra-subtype C recom-
binant with 3 breakpoints. Sequence 0193A had a long
branch and jpHMM indicated a possible CK recombinant
form.
The ML phylogenetic tree for the env gp41 contained 74
sequences and all sequences, except for 0143A, clustered
with HIV-1 subtype C sequences (Figure 5). Sequence
0143A clustered with subtype B in the env region and as
an outlier to subtype C in the gag region. SQUEAL indi-
cated that 0143A was an intra-subtype C recombinant in
the pol region. This is the first indication of a putative
unique BC recombinant sequence in Bushbuckridge,
Mpumalanga.
HIV-1 antiretroviral drug resistance mutations
Although the participants were from an antiretroviral
treatment naïve cohort, some antiretroviral drug muta-
tions were detected (Table 4). The NNRTI mutation
K103N detected on the 0143A sequence causes high-
level resistance to nevirapine (NVP), and efavirenz
(EFV). The NNRTI mutation, E138A, detected on the
0143A sequence is a polymorphism that may contribute
to reduced etravirine (ETR) and rilpivirine (RPV) sus-
ceptibility in combination with other NNRTI-resistance
mutations. The K101E mutation found on the 0189A se-
quence causes intermediate resistance to NVP and low-
level resistance to EFV, ETR, and RPV. No major PI muta-
tions were detected in the Bushbuckridge, Mpumalanga
sequences. The T74S minor PI mutation occurs in 5% of
untreated persons with subtype C viruses and is associated
with reduced NFV susceptibility [28-31].
E157Q is an integrase polymorphic accessory mutation
that is weakly selected in patients receiving raltegravir
(RAL) and causes low level resistance to RAL and elvite-
gravir (EVG). L74I is an accessory mutation for integrase.
Discussion
The investigation of the HIV subtype diversity of samples
obtained from a cohort in Bushbuckridge, Mpumalanga
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Figure 4 (See legend on next page.)
Msimanga et al. Virology Journal  (2015) 12:24 Page 8 of 13
(See figure on previous page.)
Figure 4 Phylogenetic analysis of the integrase gene, using MEGA 6. The evolutionary history was inferred by using the ML method based
on the GTR model. The tree with the highest log likelihood (−7480.4899) is shown. The percentage of trees in which the associated taxa clustered
together is shown next to the branches. A discrete Gamma distribution was used to model evolutionary rate differences among sites (5 categories (+G,
parameter = 0.3186)). The rate variation model allowed for some sites to be evolutionarily invariable ([+I], 42.6830% sites). The tree is drawn to scale,
with branch lengths measured in the number of substitutions per site. The analysis involved 55 nucleotide sequences and there were a total of 849
positions in the final dataset.
Msimanga et al. Virology Journal  (2015) 12:24 Page 9 of 13revealed, first, that the HIV-1 from these samples belong
almost entirely to HIV-1 subtype C with one BC recom-
binant; second, that the way in which the sequences
derived from these samples cluster in phylogenetic
trees suggests there has been multiple introductions of
HIV-1 into Bushbuckridge; and third, the prevalence
of antiretroviral drug resistance mutations and drug
resistance-associated polymorphisms in Bushbuckridge is
extremely low.
Bushbuckridge HIV epidemic is predominantly subtype C,
with one BC URF
The fact that the HIV samples from Bushbuckridge,
Mpumalanga, belong almost entirely to subtype C is
consistent not only with the explosive HIV-1 epidemic
in southern Africa, but also it’s very limited subtype di-
versity. HIV-1 subtype C is the most common subtype,
accounting for the majority of HIV infections in southern
Africa [4,5], while subtype B is responsible for infections
in MSM [9,12]. One putative subtype BC unique recom-
binant form was detected. This indicates that BC URFs
are not only found in the Western Cape Province [15], but
also in Mpumalanga province.
Multiple introductions of HIV-1 into Bushbuckridge
The fact that HIV-1 subtype C sequences from South
Africa tend to intermingle with HIV-1 subtype C se-
quences from Botswana, Malawi and Zambia suggests
they may have a common evolutionary origin [32,33].
The possibility of an underlying common evolutionary
origin of isolates in southern Africa is consistent with
the history of the population dynamics of the southern
African region. While the HIV-1 subtype C isolates from
Brazil and Ethiopia tend to cluster separately, the fact
that the subtype C isolate from India tends to cluster
with the subtype C isolates from southern Africa [34,35]
can be explained by the historical connections between
the Indian subcontinent and southern Africa, which
arises from the roles of both regions as former British
colonial territories.
Countries in southern Africa in which adult national
HIV prevalence rates exceeded 15% in 2007 were all
linked by the migrant labor system. This system, which
under pinned the population dynamics of both South
Africa and the broader southern African region, was
critical in shaping the patterns of population mobilityand integration that characterizing the entire region.
The migrant labor system was integral to the develop-
ment and structure of the South African economy and
apartheid. Botswana, Lesotho, Namibia, South Africa,
Swaziland, Zambia, and Zimbabwe, were all historically
linked through the migrant labor system that brought
men from as far as Zambia and Malawi to the mines ini-
tially on the Reef and subsequently elsewhere in the
country [36-39]. Migrants are more vulnerable to HIV
infection than people who hardly move, both in south-
ern Africa as in other African countries [40-42]. A 1985
survey of workers in the gold mines originating from the
entire southern African region found HIV prevalence to
be very low among South African miners but among
Malawian miners prevalence was already at 3% [36].
High infection levels are being found in Gaza province
in Mozambique, where large numbers of migrants work-
ing in South Africa originate [43]. Before and after inde-
pendence foreign migrant workers also crossed borders
to work in mines in Namibia, Botswana, Zambia, and
Zimbabwe [44-46].
Many of the countries in southern African with explo-
sive HIV/AIDS epidemic are also landlocked, which en-
tails that the region’s road transport networks does not
only link these landlocked countries to the ports in
Durban, Richards Bay and Maputo, but also facilitate
the rapid spread of HIV in the region by ensuring the
sexual networks that drive the epidemic transcend national
boundaries. The Ehlanzeni District in Mpumalanga Province
straddles the Maputo Corridor, a major trade route which
connects the Gauteng, Limpopo, and Mpumalanga prov-
inces of South Africa with Maputo, the capital of
Mozambique that also has a major port. In Mozambique,
HIV is spreading more rapidly in provinces linked by major
transport routes to Malawi, South Africa and Zimbabwe.
High infection rates have been found in Sofia province,
which is traversed by Zimbabwe’s main export route [43].
The peculiarly explosive HIV-1 epidemic in southern
Africa could also stem from the unique biological prop-
erties of subtype C. HIV-1 subtype C has an additional
NF-binding site in the long terminal repeat (LTR), a pre-
maturely truncated Rev protein, a 5′-amino-acid inser-
tion in Vpu, and a more active, catalytically efficient
protease, which may influence viral gene expression and
alter the transmissibility and pathogenesis of subtype C
isolates [31,47-52]. These unique biological properties,
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Figure 5 Phylogenetic analysis of the partial env gene, using
MEGA 6. The evolutionary history was inferred by using the ML
method based on the GTR model. The tree with the highest log
likelihood (−7290.5638) is shown. The percentage of trees in which
the associated taxa clustered together is shown next to the
branches. A discrete Gamma distribution was used to model
evolutionary rate differences among sites (5 categories (+G,
parameter = 0.6134)). The rate variation model allowed for some
sites to be evolutionarily invariable ([+I], 32.1349% sites). The tree is
drawn to scale, with branch lengths measured in the number of
substitutions per site. The analysis involved 74 nucleotide sequences
and there were a total of 402 positions in the final dataset.
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such as the CCR5 and non-syncytium-inducing pheno-
type, may account for the explosive epidemic of HIV-1
subtype C in southern Africa [53-55]. However, the add-
itional NF-κB site in HIV-1 subtype C may be biologic-
ally inactive, and enhanced activity of these individual
functions may still not be sufficient to overcome the
decreased replicative capacity of the CCR5-tropic non-
syncytium-inducing phenotype [53].
Drug resistance mutations and polymorphisms
Combination antiretroviral therapy can suppress HIV-1
replication to undetectable levels with concomitant sig-
nificant clinical outcomes. However, suboptimal sup-
pression HIV-1 replication can result in the emergence
of drug resistant virus strains. HIV-1 isolates that have
acquired mutations conferring reduced susceptibility to
antiretroviral drugs can be can be transmitted, poten-
tially limiting options for first line therapy in untreated
individuals [56]. The proportion of patients without
prior antiretroviral therapy and who are infected with a
virus resistant to at least one antiretroviral drug in
Australia, Europe, Japan and the United States of America
is 10% to 17%, while data between 2006 and 2010 suggests
that transmitted antiretroviral drug resistance amongTable 4 HIV-1 drug resistance mutations detected in the
Mpumalanga cohort
Isolate Minor PI
Mutations
NNRTI
mutations
Integrase
mutations
0005A None None L74I
0042A T74S None None
0081A None None E157Q
0143A None K103N None
E138A
0173A T74S None None
0189A None K101E None
0192A T74S None None
0198A None None L74I
0206A T74S None None
Msimanga et al. Virology Journal  (2015) 12:24 Page 11 of 13those starting antiretroviral treatment in low- and middle-
income countries increasing [2].
South Africa has the largest antiretroviral treatment
program in the world. Besides its unprecedented scale,
the antiretroviral treatment programme in South Africa
is also being rolled out rapidly, such that while only
833653 adults and 86270 children were on antiretroviral
treatment through the public sector in South Africa by
the end of 2009, the number of those on treatment by
2012 had increased to 2010340 adults and 140541 chil-
dren [2,3,16].
While the HIV-1 sequences used in this study are derived
from treatment-naïve participants from Bushbuckridge,
Mpumalanga, the K103N antiretroviral drug resistance
mutation was detected. This suggests the participants
from Bushbuckridge, Mpumalanga may either have under-
gone antiretroviral treatment or that they were infected
with antiretroviral drug resistant strains [28-31]. The
E138A mutation selected for by riplivirine/etravirine, must
also be a transmitted mutation. Both riplivirine/etravirine
are not part of the first and second line ART regimens in
South Africa, while etravirine is part of the third line regi-
men. Patients in Mpumalanga only started receiving third
line ART 2013.
Limitations of this study
The limitations of the study include a relatively small
sample size; DNA amplification was not successful for
up to 71% of the samples of the partial pol PR/RT sub-
genomic region; use of partial gene regions to assign
viral subtypes, potentially allowing recombinant viruses
to be missed, the use of direct; population sequencing
may result in the lack of detection of minority-
population viruses; which can lead to an underestima-
tion of viral diversity and drug resistance mutations.
Conclusions
HIV diversity may have implications for diagnosis,
pathogenesis, transmission, clinical management and
vaccine development. Phylogenetic analysis of HIV se-
quence diversity has allowed vital insights into the ori-
gin, evolution and spread of HIV, which suggests it is
imperative to maintain HIV-1 molecular epidemiology
surveillance. The extensive population mobility arising
from the historical and structural migrant labor system
characterizing South Africa, and the concomitant over-
lapping of sexual networks, seems to have precluded the
possibility of distinct geographical lineages developing.
However, the demise of apartheid, in particular the end
of influx control measures, may have a significant impact
on patterns of population mobility and settlement in
South Africa, which in turn may affect the patterns of
transmission of HIV and ultimately it’s evolution. The
possible emergence of various HIV-1 recombinantscould suggest that the migration of people into South
Africa from Central, West and eastern Africa could also
impact on the character and dynamics of the HIV/AIDS
epidemic in South Africa.Additional files
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